# A Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either 2- Or 3-Dose Regimens In Healthy Subjects Aged ≥11 To <19 Years

> **NCT01299480** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 1714 (actual)

## Conditions studied

- Meningococcal Vaccine

## Interventions

- **BIOLOGICAL:** Vaccine
- **BIOLOGICAL:** Vaccine
- **BIOLOGICAL:** Vaccine
- **BIOLOGICAL:** Vaccine
- **BIOLOGICAL:** Vaccine

## Key facts

- **NCT ID:** NCT01299480
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03-03
- **Primary completion:** 2012-05-03
- **Final completion:** 2012-09-18
- **Target enrollment:** 1714 (ACTUAL)
- **Last updated:** 2022-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01299480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01299480, "A Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either 2- Or 3-Dose Regimens In Healthy Subjects Aged ≥11 To <19 Years". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01299480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*